Why Is PFIZER INC (PFE) Stock Moving Today?

PFE stock is moving higher today, up 1.1% to $25.11 in midday trading, as legal developments involving its partnership with BioNTech on the COVID-19 vaccine continue to unfold. The stock opened at $24.86 and has traded in a narrow range, with a session high of $25.36 at 10:55 AM ET. The rise comes amid new patent infringement lawsuits filed by Arbutus and its exclusive licensee, Genevant, in Canada and Europe, which allege that the vaccine infringes on their lipid nanoparticle technology.

Arbutus and Genevant have filed three international lawsuits targeting Pfizer and BioNTech, seeking to enforce their intellectual property rights. These legal actions follow recent news that Arbutus received a first payment from its settlement agreement with Moderna. The lawsuits add to the ongoing legal scrutiny of the vaccine’s technology and could lead to protracted litigation. Meanwhile, analysts from BMO Capital, Guggenheim, and B of A Securities have maintained their positions on the stock, with price targets adjusted downward to $30, $35, and $26 respectively.

What The Data Shows: The stock has traded in a 52-week range of $23.11 to $28.75 and has moved up 4.5% over the last eight sessions. Trading volume has been steady at 39.5 million shares, matching the 3-month daily average. Recent insider transactions include a $51,000 sale by Jennifer B. Damico, SVP and Controller, while congressional trades show a mix of small buys and sells by Donald J. Trump over the past two weeks. The stock has printed eight fresh 52-week lows on July 16, but remains within its recent price trend.

What To Watch: Investors should monitor the legal developments closely, as the outcome of the lawsuits could impact the company’s partnerships and intellectual property strategy. No earnings date is scheduled in the near term, but coverage breadth from analysts remains a key factor to watch.